arrow_back Trending Legislation
Share share

Urging FDA to Reevaluate Safety of Chemical Abortion Drugs

The House of Representatives is urging the Food and Drug Administration (FDA) to reevaluate the safety of all chemical abortion drugs. This call comes in light of new independent studies suggesting a significantly higher rate of serious complications than previously reported. Citizens can expect a public release of a full safety review, which could impact the availability and use of these drugs.
Key points
Request for the FDA to reevaluate the safety of chemical abortion drugs based on recent independent studies.
Demand for a public release of a comprehensive safety review of these drugs, including real-world outcomes and complications.
Highlighting concerns about increased risks of complications, coercion, and misuse associated with expanded access to these drugs.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.
Print number: HRES 803
Sponsor: Rep. Rose, John W. [R-TN-6]
Process start date: 2025-10-10
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Urging FDA to Reevaluate Safety of Chemical Abortion Drugs

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HRES 803.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-10-10.

What are the main provisions?

Key points include:

  • Request for the FDA to reevaluate the safety of chemical abortion drugs based on recent independent studies.
  • Demand for a public release of a comprehensive safety review of these drugs, including real-world outcomes and complications.
  • Highlighting concerns about increased risks of complications, coercion, and misuse associated with expanded access to these drugs.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Rose, John W. [R-TN-6].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

Analysis and Potential Impact of HRES 803

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health